The global continuous renal replacement therapy (CRRT) market size was estimated to be USD 1.57 billion in 2023 and is expected to reach at USD 3.79 billion by 2034 with a CAGR of 8.34% during the forecast period 2024-2034. Surge in prevalence of acute kidney injury (AKI) & sepsis, growing number of hospitals & urgent care facilities, increasing rate of hospital admissions, rising product launches by market players, surge in investment by major market players, growing demand for advanced CRRT devices, increasing technological advancements, rising introduction of sophisticated CRRT machines, growing focus on development of improved pediatric CRRT products, and increasing introduction of novel products are some of the key factors boosting the market growth.
Increasing introduction of novel products is predicted to boost the market growth during the forecast period. Continuous renal replacement therapy (CRRT) is a gradual and continuous process for purifying blood outside the body. It typically extends over a period of 24 hours to multiple days, with the gentle removal of excess fluids and uremic toxins. This method relies on physiological principles such as diffusion, ultrafiltration, convection, and adsorption. Consequently, the increasing number of patients with renal disorders is expected to drive the demand for technologically advanced products. For instance, in August 2022, Fresenius Medical Care North America's Renal Therapies Group has introduced Speedswap, a new feature for the NxStage System OneTM with NxViewTM. Speedswap enables the replacement of a dialysis filter that has compromised flow without the need to replace the entire cartridge.
By age group, adults was the highest revenue-grossing segment in the global continuous renal replacement therapy (CRRT) market in 2023 owing to the surge in demand for invisible braces among population base with AKI, growing number of hospitalizations among adult population, the large availability of CRRT system, rising introduction of advanced systems. For instance, in March 2022, Nipro, a prominent manufacturer of renal products, has officially launched the SURDIAL DX, a state-of-the-art hemodialysis system intended to provide optimal dialysis treatment. Additionally, pediatrics is predicted to grow at fastest CAGR during the forecast period owing to surge in prevalence of actue kidney disorders among pediatric population and increasing technological developments.
By end-user, hospitals was the highest revenue-grossing segment in the global continuous renal replacement therapy (CRRT) market in 2023 owing to the increasing prevalence of AKI, growing adoption of dialysis procedures, and rising approvals by regulatory authorities. For instance, in August 2023, Quanta Dialysis Technologies has announced its receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for an extended indication of the Quanta Dialysis System. This compact and user-friendly hemodialysis device is now approved for two modalities of continuous renal replacement therapy (CRRT): continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF). Additionally, ambulatory care is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of novel therapies and surge in government initiatives & reimbursement.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of geriatric population, surge in diagnosis of kidney disorders, growing adoption of sedentary lifestyles & unhealthy food habits, and increasing funding by major market players. For instance, in August 2022, The U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) have unveiled a new prize competition through the Kidney Innovation Accelerator (KidneyX) initiative. This competition is aimed at advancing the development of a fully operational bioartificial kidney. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of diabetes, CKD & hypertension, rising healthcare expenditure, surge in investment for research & development activities, and growing initiatives by market players. For instance, in September 2023, Cytecare Hospitals has inaugurated the Institute for Dialysis and Renal Diseases, signaling a dedicated effort to address dialysis and renal health concerns.
Increasing introduction of novel products is predicted to boost the market growth during the forecast period. Continuous renal replacement therapy (CRRT) is a gradual and continuous process for purifying blood outside the body. It typically extends over a period of 24 hours to multiple days, with the gentle removal of excess fluids and uremic toxins. This method relies on physiological principles such as diffusion, ultrafiltration, convection, and adsorption. Consequently, the increasing number of patients with renal disorders is expected to drive the demand for technologically advanced products. For instance, in August 2022, Fresenius Medical Care North America's Renal Therapies Group has introduced Speedswap, a new feature for the NxStage System OneTM with NxViewTM. Speedswap enables the replacement of a dialysis filter that has compromised flow without the need to replace the entire cartridge.
By product, consumables was the highest revenue-grossing segment in the global continuous renal replacement therapy (CRRT) market in 2023 owing to rising utilization of charcoal filters, haemofilter, fluid & other consumable products in CRRT and growing demand for acute dialysis products. For instance, in January 2023, Peconic Bay Medical Center has revealed the introduction of an advanced dialysis program, Continuous Renal Replacement Therapy (CRRT), designed to provide treatment to patients dealing with kidney damage. Additionally, system segment is predicted to grow at fastest CAGR during the forecast period owing to the rising utilization of renal therapy delivery, surge in technological advancements such as high-volume permeability of CRRT, and integration of Electronic Medical Record (EMR) connectivity, growing focus on development of innovative devices
By modality, continuous venovenous hemofiltration (CVVH) was the highest revenue-grossing segment in the global continuous renal replacement therapy (CRRT) market in 2023 owing to the surge in prevalence of fluid overload cases and increasing demand for advanced treatment options. Additionally, continuous venovenous hemodiafiltration (CVVHDF) is predicted to grow at fastest CAGR during the forecast period owing to the rising prevalence of acute renal failure and growing launch of new products. For instance, in April 2022, Baxter International has disclosed that its ST set for continuous renal replacement therapy has received FDA (510k) clearance. This pre-connected extracorporeal system employs a semipermeable membrane for blood purification and is designed for use with the PrisMax or Prismaflex platforms.By age group, adults was the highest revenue-grossing segment in the global continuous renal replacement therapy (CRRT) market in 2023 owing to the surge in demand for invisible braces among population base with AKI, growing number of hospitalizations among adult population, the large availability of CRRT system, rising introduction of advanced systems. For instance, in March 2022, Nipro, a prominent manufacturer of renal products, has officially launched the SURDIAL DX, a state-of-the-art hemodialysis system intended to provide optimal dialysis treatment. Additionally, pediatrics is predicted to grow at fastest CAGR during the forecast period owing to surge in prevalence of actue kidney disorders among pediatric population and increasing technological developments.
By end-user, hospitals was the highest revenue-grossing segment in the global continuous renal replacement therapy (CRRT) market in 2023 owing to the increasing prevalence of AKI, growing adoption of dialysis procedures, and rising approvals by regulatory authorities. For instance, in August 2023, Quanta Dialysis Technologies has announced its receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for an extended indication of the Quanta Dialysis System. This compact and user-friendly hemodialysis device is now approved for two modalities of continuous renal replacement therapy (CRRT): continuous venovenous hemodialysis (CVVHD) and slow continuous ultrafiltration (SCUF). Additionally, ambulatory care is predicted to grow at fastest CAGR during the forecast period owing to the rising adoption of novel therapies and surge in government initiatives & reimbursement.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of geriatric population, surge in diagnosis of kidney disorders, growing adoption of sedentary lifestyles & unhealthy food habits, and increasing funding by major market players. For instance, in August 2022, The U.S. Department of Health and Human Services (HHS) and the American Society of Nephrology (ASN) have unveiled a new prize competition through the Kidney Innovation Accelerator (KidneyX) initiative. This competition is aimed at advancing the development of a fully operational bioartificial kidney. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing prevalence of diabetes, CKD & hypertension, rising healthcare expenditure, surge in investment for research & development activities, and growing initiatives by market players. For instance, in September 2023, Cytecare Hospitals has inaugurated the Institute for Dialysis and Renal Diseases, signaling a dedicated effort to address dialysis and renal health concerns.
Segmentation: Continuous Renal Replacement Therapy (CRRT) Market Report 2023 - 2034
Continuous Renal Replacement Therapy (CRRT) Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Systems
- Consumables
Continuous Renal Replacement Therapy (CRRT) Market Analysis & Forecast by Modality 2023 - 2034 (Revenue USD Bn)
- Continuous Venovenous Hemodiafiltration (CVVHDF)
- Continuous Venovenous Hemodialysis (CVVHD)
- Slow Continuous Ultra-Filtration (SCUF)
- Continuous Venovenous Hemofiltration (CVVH)
Continuous Renal Replacement Therapy (CRRT) Market Analysis & Forecast by Age Group 2023 - 2034 (Revenue USD Bn)
- Adults
- Pediatrics/Neonates
Continuous Renal Replacement Therapy (CRRT) Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Ambulatory Care
- Hospitals
- Homecare
- Others
Continuous Renal Replacement Therapy (CRRT) Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Continuous Renal Replacement Therapy (CRRT) Market: Product Estimates & Trend Analysis
8. Continuous Renal Replacement Therapy (CRRT) Market: Modality Estimates & Trend Analysis
9. Continuous Renal Replacement Therapy (CRRT) Market: Age Group Estimates & Trend Analysis
10. Continuous Renal Replacement Therapy (CRRT) Market: End-user Estimates & Trend Analysis
11. Regional Market Analysis
12. North America Continuous Renal Replacement Therapy (CRRT) Market
13. Europe Global Continuous Renal Replacement Therapy (CRRT) Market
14. Asia Pacific Global Continuous Renal Replacement Therapy (CRRT) Market
15. Latin America Global Continuous Renal Replacement Therapy (CRRT) Market
16. MEA Global Continuous Renal Replacement Therapy (CRRT) Market
17. Competitor Analysis
18. Company Profiles
Companies Mentioned
- Nipro Corporation
- NxStage Medical Inc.
- Toray Industries Inc.
- B. Braun Melsungen Ag
- SWS Hemodialysis Care
- Chongqing Shanwaishan Science and Technology
- Anjue Medical Equipment Co. Ltd
- Medites Pharma spol. s.r.o
- Ningbo Tianyi Medical Devices
- Medical Components Inc.
- Cytosorbents
- Medtronic plc
- Baxter International
- NIKKISO Co. Ltd
- Medica S.p.A
- Fresenius Medical Care
- Asahi Kasei Corporation
- Infomed SA
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 1.57 Billion |
| Forecasted Market Value ( USD | $ 3.79 Billion |
| Compound Annual Growth Rate | 8.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
